1. In this phase 3 randomized controlled trial involving patients with muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab significantly ...
1. In the management of adult patients with metastatic urothelial carcinoma (MUC), enfortumab vedotin plus pembrolizumab (EV/P) was well-tolerated and ...
1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma. 2. ...
1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma. 2. ...
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in
